



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

May 22, 2015

Corporate Relationship Department  
The Bombay Stock Exchange Limited  
Dalal Sreet, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully  
**For NATCO Pharma Limited**

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA, Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref:PR/01/2015-16**

**Press Release**

Hyderabad, 22<sup>nd</sup> May, 2015

### **NATCO records Rs.840 crores net revenues for the year ended March 2015**

The Board of NATCO Pharma Limited (NPL) met in Hyderabad today and adopted the consolidated audited accounts of the company for the year ended 31<sup>st</sup> March, 2015.

NPL recorded an aggregate of Rs.840.18 crores in consolidated net revenues for the year ended on 31<sup>st</sup> March, 2015, as against Rs.755.60 crores for last year, reflecting a growth of 11.20%.

The net profit, after tax, on a consolidated basis, was recorded as Rs.134.61 crores. This includes two exceptional items:

- (a) A decrease in profit on account of an extraordinary charge of Rs.15.13 crores due to a legal settlement.
- (b) An increase in profit on account of a reversal of deferred tax liability of Rs.31.17 crores.

For the quarter ended March 31<sup>st</sup>, 2015, the Company recorded a net revenue of Rs.204 crores, on a consolidated basis, as against Rs.193.76 crores during Q4, FY 2014, posting an increase of 5.28%, quarter-on-quarter basis. The profits, after tax, on a consolidated basis, was recorded as Rs.54.44 crores, which includes a deferred tax reversal.

---

Forwarded for favor of publication

**For NATCO Pharma Limited**

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)